Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Journal for ImmunoTherapy of Cancer, 7.2019, Nr. 1, Art. 299, doi:10.1186/s40425-019-0800-0
- Event
-
Veröffentlichung
- (where)
-
Frankfurt am Main
- (who)
-
Universitätsbibliothek Johann Christian Senckenberg
- (when)
-
2019
- Creator
-
Heppt, Markus V.
Amaral, Teresa
Kähler, Katharina C.
Heinzerling, Lucie
Hassel, Jessica C.
Meissner, Markus
Kreuzberg, Nicole
Loquai, Carmen
Reinhardt, Lydia
Utikal, Jochen
Dabrowski, Evelyn
Gesierich, Anja
Pföhler, Claudia
Terheyden, Patrick
Thoms, Kai-Martin
Zimmer, Lisa
Eigentler, Thomas
Kirchberger, Michael Constantin
Stege, Henner Maximilian
Meier, Friedegund
Schlaak, Max
Berking, Carola
- URN
-
urn:nbn:de:hebis:30:3-533420
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:43 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Heppt, Markus V.
- Amaral, Teresa
- Kähler, Katharina C.
- Heinzerling, Lucie
- Hassel, Jessica C.
- Meissner, Markus
- Kreuzberg, Nicole
- Loquai, Carmen
- Reinhardt, Lydia
- Utikal, Jochen
- Dabrowski, Evelyn
- Gesierich, Anja
- Pföhler, Claudia
- Terheyden, Patrick
- Thoms, Kai-Martin
- Zimmer, Lisa
- Eigentler, Thomas
- Kirchberger, Michael Constantin
- Stege, Henner Maximilian
- Meier, Friedegund
- Schlaak, Max
- Berking, Carola
- Universitätsbibliothek Johann Christian Senckenberg
Time of origin
- 2019
Other Objects (12)
Discontinuation of BRAF/MEK-directed targeted therapy after complete remission of metastatic melanoma — a retrospective multicenter ADOReg study
Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment—A Retrospective Multicenter Analysis
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma : a retrospective multicenter DeCOG study
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
Primary Resistance to Immune Checkpoint Inhibitors in Patients with Metastatic Melanoma : Prognosis, Subsequent Therapies and Survival
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis
Digital quantification of tumor PD-L1 predicts outcome of PD-1-based immune checkpoint therapy in metastatic melanoma
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma
Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study
Discontinuation of BRAF/MEK-directed targeted therapy after complete remission of metastatic melanoma — a retrospective multicenter ADOReg study
Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment—A Retrospective Multicenter Analysis
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma : a retrospective multicenter DeCOG study
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
Primary Resistance to Immune Checkpoint Inhibitors in Patients with Metastatic Melanoma : Prognosis, Subsequent Therapies and Survival
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis
Digital quantification of tumor PD-L1 predicts outcome of PD-1-based immune checkpoint therapy in metastatic melanoma
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma
Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study
Discontinuation of BRAF/MEK-directed targeted therapy after complete remission of metastatic melanoma — a retrospective multicenter ADOReg study
Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment—A Retrospective Multicenter Analysis
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma : a retrospective multicenter DeCOG study
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
Primary Resistance to Immune Checkpoint Inhibitors in Patients with Metastatic Melanoma : Prognosis, Subsequent Therapies and Survival
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis
Digital quantification of tumor PD-L1 predicts outcome of PD-1-based immune checkpoint therapy in metastatic melanoma
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma